159 related articles for article (PubMed ID: 9595966)
21. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
Blass JP; Cyrus PA; Bieber F; Gulanski B
Alzheimer Dis Assoc Disord; 2000; 14(1):39-45. PubMed ID: 10718203
[TBL] [Abstract][Full Text] [Related]
22. Evaluating response to metrifonate.
Tariot PN
J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
[TBL] [Abstract][Full Text] [Related]
24. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
25. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
28. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
[TBL] [Abstract][Full Text] [Related]
29. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959
[TBL] [Abstract][Full Text] [Related]
30. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
[TBL] [Abstract][Full Text] [Related]
32. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
33. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
[TBL] [Abstract][Full Text] [Related]
34. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
35. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
36. Metrifonate: a new agent for the treatment of Alzheimer's disease.
Williams BR
Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
[TBL] [Abstract][Full Text] [Related]
37. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
38. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
39. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
40. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Kaufer D
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():8-14. PubMed ID: 9718229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
